Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of neoadjuvant DCF with or without short-course radiotherapy for locally advanced esophageal cancer
jRCT1061260067Phase 2Recruiting
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin and fluorouracil in esophageal cancer (2 arms). Primary endpoint: Primary composite endpoint. Started Sep 2026; status: recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1061260067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260067.